Pluri Inc. (TLV:PLUR)

Israel · Delayed Price · Currency is ILS · Price in ILA

1,137.00

-33.00 (-2.82%)

Feb 20, 2026, 1:44 PM IDT

Revenue by Segment

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Research, Development, Clinical Trials and Manufacturing of Cell Therapeutics	1.34M	326.00K	287.00K	234.00K		23.00K
Research, Development, Clinical Trials and Manufacturing of Cell Therapeutics Growth	309.82%	13.59%	22.65%	-		-57.41%
Total	1.34M	326.00K	287.00K	234.00K		23.00K
Total Growth	309.82%	13.59%	22.65%	-		-57.41%

Revenue by Geography

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Israel	1.34M	326.00K	287.00K	234.00K		23.00K
Israel Growth	309.82%	13.59%	22.65%	-		-57.41%
Total	1.34M	326.00K	287.00K	234.00K		23.00K
Total Growth	309.82%	13.59%	22.65%	-		-57.41%

Source: S&P Global Market Intelligence.